Trying to capitalize on those positive results to lock in market share, the pair made a first move toward a dramatically lower price, cutting Praluent's postrebate net price to the range of $4,500 to $8,000—within ICER's recommendation—and won themselves an exclusive spot on Express Scripts' preferred formulary. Amgen didn't just sit around. Last October, in what may be a first for pharma, Amgen slashed the list price of Repatha by 60% to $5,850 per year.